Abivax S.A. ADR

NASDAQ • Healthcare • Biotechnology • Quote as of 09/23/2026 16:00

Company Profile

IndustryBiotechnology

SectorHealthcare

ExchangeNASDAQ

Market Capitalization8,130.31 mln

Float79.12 mln

Earnings Date09/21/2026

1-Year Forecast

164.00

Transformational upside

Relative Strength

4 / 100

Severely lagging

Debt / Equity

0.00

Debt-free

Pre-Tax Margin

17,652%

Exceptional margin

ROE

-124

Deeply negative

ROA

-80.24

Deeply negative

Business Description

ABIVAX is a Paris-based drug development company founded in 2013, focused on creating treatments that work with the body's own immune system to manage long-term inflammatory conditions. Its most advanced medicine, obefazimod, is currently being tested in late-stage trials for ulcerative colitis and earlier-stage trials for Crohn's disease.

Key Fundamentals

EPS-6.12

ROE-124

ROIC-354

ROA-80.24

Interest Cover-9.37

EBITDA, mln-443

EV / EBITDA-17.79

EV / EBIT-17.73

Quote Details

Last 94.13

Change -4.16 (-4.23%)

Open 98.30

Volume 2,633,458

Turnover 247,887,392

Average Volume 1,210,090

Financial Ratios

Pre-Tax Profit Margin17,652

Leverage Ratio1.26

Current Ratio8.25

Price / Book15.19

Price / Tangible Book16.14

Debt / Equity0.00

Financial Strength

1-Year Target Price164.00

Short Ratio8.05

Short % of Float8.07

Price Performance & Relative Strength

Period	Price Performance	Relative Strength
1 Week	-7.92%	8 / 100
1 Month	-18.96%	11 / 100
2 Months	-3.46%	40 / 100
6 Months	-14.56%	22 / 100
1 Year	14.5%	70 / 100